Exparel 133 MG/10 ML vial 10ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRWD3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,082
Award facts
- Contract value 100% obligated
- $3,082.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,082.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL (133 mg/10 ml vial). This firm fixed-price delivery order, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that positions the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations.
EXPAREL is a specialty pharmaceutical product used in surgical applications for local anesthesia and pain management. DMS Pharmaceutical Group's established performance across a diverse product portfolio—including oncology treatments, biologics, vaccines, and specialty surgical products—demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system. The PPV-G GEN V program represents a broader $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply to military healthcare facilities worldwide, with DMS Pharmaceutical Group serving as one of multiple regional prime vendor contractors supporting this critical defense logistics mission.
Quick answers
Who was awarded contract SPE2DR26FRWD3?
SPE2DR26FRWD3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FRWD3 worth?
The government has obligated $3,082 on SPE2DR26FRWD3.
Is contract SPE2DR26FRWD3 an order under another contract?
Yes. SPE2DR26FRWD3 is a delivery order under SPE2DR25D9767, an indefinite delivery contract.
Was contract SPE2DR26FRWD3 competed?
The extent of competition for SPE2DR26FRWD3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award